Abstract: A botanical extract for use in skin care, wherein the botanical extract is at least an extract from the testa of the seed of Anacardium occidentale L.

Abstract: Plant-based inhibitors of MMP-9 that also function as PPAR-? agonists, and the use of such plant-based inhibitors/agonists in modulating metabolic disorders is disclosed. The plant-based inhibitor/agonist is at least an extract obtained from the genus Anacardium.

Abstract: A botanical extract that exhibits anti-inflammatory activity, wherein the botanical extract is at least an extract from the genus Anacardium.

Abstract: A botanical extract that exhibits antioxidant activity, wherein the botanical extract is at least an extract from the leaf of a plant from the genus Vaccinium.

Abstract: Plant-based inhibitors of MMP-9 that also function as PPAR-? agonists, and the use of such plant-based inhibitors/agonists in modulating metabolic disorders is disclosed. The plant-based inhibitor/agonist is at least an extract obtained from the leaf of the genus Vaccinium.

Abstract: A botanical extract that exhibits anti-inflammatory activity, wherein the botanical extract is at least an extract from the leaf of Vaccinium macrocarpon.

Abstract: Plant-based inhibitors of MMP-9 that also function as PPAR-? agonists, and the use of such plant-based inhibitors/agonists in modulating metabolic disorders is disclosed. The plant-based inhibitor/agonist is at least an extract obtained from the genus Anacardium.

Abstract: A botanical extract for use in skin care, wherein the botanical extract is at least an extract from the testa of the seed of Anacardium occidentale L.

Abstract: A botanical extract that exhibits anti-inflammatory activity, wherein the botanical extract is at least an extract from the genus Anacardium.

Abstract: A botanical extract that exhibits antioxidant activity, wherein the botanical extract s at least an extract from the genus Anacardium.

Abstract: Topical compositions, packaging systems and methods for improving the appearance of skin or at least one sign of aging in skin are described.

Abstract: Topical compositions, packaging systems and methods for improving the appearance of skin or at least one sign of aging in skin including Kachnar are described.

Abstract: Topical compositions, packaging systems and methods for improving the appearance of skin or at least one sign of aging in skin including Kachnar are described.

Abstract: Compositions for topical use and having a melanin synthesis-inhibiting activity that include an amount of a botanical extract of at least one of Aspalathus Linearis, Matricaria, Saxifraga, Astragalus, Taraxacum officinale/mongolicum, Ferula varia/foetida, Carthamus tinctorius, Sophora flavescentis, or Chrysanthemum morifolium effective to reduce melanin synthesis are described. Methods for inhibiting melanin synthesis and for skin whitening are also described.

Abstract: Disclosed herein are dietary supplement compositions and methods for increasing or stimulating bone growth, decreasing or preventing bone resorption, increasing bone strength, improving bone structure, and improving bone architecture comprising a first composition comprising a combination of at least two of: quercetin, Rehmannia sp., Rehmannia sp. root, Siberian ginseng, Sophora japonica, licorice, and ipriflavone, wherein the combination of the first composition increases bone morphogenic protein-2 gene, promoter or protein expression; and a second composition comprising an extract of pomegranate in combination with at least one of Siberian ginseng, Ginkgo biloba, green tea, Sophora japonica, Rehmannia sp., grape seed, Dong Quai, and ipriflavone, wherein the combination of the second composition inhibits the expression of RANK-L.

Abstract: Topical compositions, packaging systems and methods for improving the appearance of skin or at least one sign of aging in skin are described.

Abstract: Disclosed herein are dietary supplement compositions and methods for increasing or stimulating bone growth, decreasing or preventing bone resorption, increasing bone strength, improving bone structure, and improving bone architecture comprising a first composition comprising a combination of at least two of: quercetin, Rehmannia sp., Rehmannia sp. root, Siberian ginseng, Sophora japonica, licorice, and ipriflavone, wherein the combination of the first composition increases bone morphogenic protein-2 gene, promoter or protein expression; and a second composition comprising an extract of pomegranate in combination with at least one of Siberian ginseng, Ginkgo biloba, green tea, Sophora japonica, Rehmannia sp., grape seed, Dong Quai, and ipriflavone, wherein the combination of the second composition inhibits the expression of RANK-L.

Abstract: Compositions for topical use and having a melanin synthesis-inhibiting activity that include an amount of a botanical extract of at least one of Aspalathus Linearis, Matricaria, Saxifraga, Astragalus, Taraxacum officinale/mongolicum, Ferula varia/foetida, Carthamus tinctorius, Sophora flavescentis, or Chrysanthemum morifolium effective to reduce melanin synthesis are described. Methods for inhibiting melanin synthesis and for skin whitening are also described.

Abstract: A composition for inhibiting ketohexokinase, for example, ketohexokinase-C (KHK-C) activity, may include a plant extract exhibiting at least IC50 (i.e., 50% KHK-C inhibition at a concentration in the range of from about 0.1 ?g/mL to about 1000 ?g/mL. The composition may be in a form suitable for oral ingestion. A method for inhibiting KHK-C activity in a subject may include administering a plant extract that exhibits at least 50% KHK-C inhibition at a concentration from about 0.1 ?g/mL to about 1000 ?g/mL. The administering may be done to treat or prevent at least one of sugar addiction, obesity, or metabolic syndrome. The administering may be done to provide a diminished craving in the subject from at least one member selected from the group consisting of craving of sugar, fructose, fructose-containing sugars, carbohydrates, and combinations thereof. The subject may be pre-diabetic, diabetic and or insulin resistant.

Abstract: A topical composition includes an alcohol-extracted Salvia hispanica seed extract in a glycol carrier in an amount effective for inhibiting melanin content in an individual. The extract may be extracted in a C1-C4 ethanol and re-suspended in a glycol carrier with one or more permeation enhancers. The topical composition may further include a Punica granatum extract. Methods for making and using the composition for whitening skin in an individual are also described.